IDH2 and central nervous system cancer: Interestingly, the oncometabolite 2-HG produced by IDH-mutant tumors has been shown to inhibit KDM5 histone lysine demethylation, contributing to its transforming influence in IDH-mutant leukemia and glioma [148].